J L Burns

Summary

Affiliation: Children's Hospital and Regional Medical Center
Country: USA

Publications

  1. ncbi request reprint Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis
    J L Burns
    Division of Infectious Disease, Department of Pediatrics, University of Washington and Children s Hospital and Regional Medical Center, Seattle, WA 98105, USA
    J Infect Dis 183:444-52. 2001
  2. ncbi request reprint Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis
    J L Burns
    Division of Infectious Disease, Children s Hospital and Regional Medical Center, 4800 Sand Point Way N E, CH 32, Seattle, WA 98105, USA
    J Infect Dis 179:1190-6. 1999
  3. pmc Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients
    J L Burns
    Department of Pediatrics, Division of Infectious Disease, University of Washington, Seattle, Washington, USA
    J Clin Microbiol 38:1818-22. 2000
  4. ncbi request reprint Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients
    J L Burns
    Department of Pediatrics, Division of Infectious Disease, Children s Hospital and Regional Medical Center, University of Washington, P O Box 5371 CH 32, Seattle, WA 98105 0371, USA
    Diagn Microbiol Infect Dis 39:257-60. 2001
  5. pmc Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis
    R M Shawar
    PathoGenesis Corporation, Department of Pediatrics, University of Washington, and Children s Hospital and Regional Medical Center, Seattle, Washington 98119, USA
    Antimicrob Agents Chemother 43:2877-80. 1999
  6. ncbi request reprint Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis
    M Rosenfeld
    Cystic Fibrosis Research Center, Children s Hospital and Regional Medical Center, Seattle, Washington 98105, USA
    Pediatr Pulmonol 32:356-66. 2001
  7. ncbi request reprint Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment
    D L MacLeod
    Department of Research Biology, PathoGenesis Corp, Seattle, WA 98119, USA
    J Infect Dis 181:1180-4. 2000
  8. pmc Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection
    J P Clancy
    Department of Pediatrics, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
    Thorax 68:818-25. 2013
  9. pmc Invasion of respiratory epithelial cells by Burkholderia (Pseudomonas) cepacia
    J L Burns
    Division of Infectious Disease, Children s Hospital and Medical Center, Seattle, Washington 98105, USA
    Infect Immun 64:4054-9. 1996
  10. ncbi request reprint Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis
    M Rosenfeld
    Division of Pulmonary Medicine, Children's Hospital and Regional Medical Center, Seattle, Washington 98105, USA
    J Pediatr 139:572-7. 2001

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis
    J L Burns
    Division of Infectious Disease, Department of Pediatrics, University of Washington and Children s Hospital and Regional Medical Center, Seattle, WA 98105, USA
    J Infect Dis 183:444-52. 2001
    ..On the basis of combined culture and serologic results, 97.5% of patients had evidence of infection by age 3 years, which suggests that P. aeruginosa infection occurs early in CF and may be intermittent or undetectable by culture...
  2. ncbi request reprint Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis
    J L Burns
    Division of Infectious Disease, Children s Hospital and Regional Medical Center, 4800 Sand Point Way N E, CH 32, Seattle, WA 98105, USA
    J Infect Dis 179:1190-6. 1999
    ..aeruginosa with a tobramycin MIC >/=16 microgram/mL to define a new break point on the basis of clinical response...
  3. pmc Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients
    J L Burns
    Department of Pediatrics, Division of Infectious Disease, University of Washington, Seattle, Washington, USA
    J Clin Microbiol 38:1818-22. 2000
    ..1 and 2.2% major errors (false resistance). Overall, both agar diffusion methods appear to be broadly acceptable for routine clinical use in susceptibility testing of CF isolates of P. aeruginosa...
  4. ncbi request reprint Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients
    J L Burns
    Department of Pediatrics, Division of Infectious Disease, Children s Hospital and Regional Medical Center, University of Washington, P O Box 5371 CH 32, Seattle, WA 98105 0371, USA
    Diagn Microbiol Infect Dis 39:257-60. 2001
    ....
  5. pmc Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis
    R M Shawar
    PathoGenesis Corporation, Department of Pediatrics, University of Washington, and Children s Hospital and Regional Medical Center, Seattle, Washington 98119, USA
    Antimicrob Agents Chemother 43:2877-80. 1999
    ..5%) were shown to possess known aminoglycoside-modifying enzymes; the remaining were presumably resistant by an incompletely understood mechanism often referred to as "impermeability."..
  6. ncbi request reprint Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis
    M Rosenfeld
    Cystic Fibrosis Research Center, Children s Hospital and Regional Medical Center, Seattle, Washington 98105, USA
    Pediatr Pulmonol 32:356-66. 2001
    ..Our findings provide a foundation for future studies of early intervention in CF lung disease, including antimicrobial and anti-inflammatory therapy...
  7. ncbi request reprint Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment
    D L MacLeod
    Department of Research Biology, PathoGenesis Corp, Seattle, WA 98119, USA
    J Infect Dis 181:1180-4. 2000
    ..These findings suggest that impermeability resistance occurs in only a fraction of the P. aeruginosa population in lungs of persons with CF and that this form of resistance arises by a process involving multiple small changes in MIC...
  8. pmc Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection
    J P Clancy
    Department of Pediatrics, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
    Thorax 68:818-25. 2013
    ..Arikace is a liposomal amikacin preparation for aerosol delivery with potent Pseudomonas aeruginosa killing and prolonged lung deposition...
  9. pmc Invasion of respiratory epithelial cells by Burkholderia (Pseudomonas) cepacia
    J L Burns
    Division of Infectious Disease, Children s Hospital and Medical Center, Seattle, Washington 98105, USA
    Infect Immun 64:4054-9. 1996
    ..Cytochalasin D, but not colchicine, inhibited invasion, suggesting a role for microfilaments but not microtubules. The invasion phenotype in B. cepacia may be an important virulence factor for CF infections...
  10. ncbi request reprint Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis
    M Rosenfeld
    Division of Pulmonary Medicine, Children's Hospital and Regional Medical Center, Seattle, Washington 98105, USA
    J Pediatr 139:572-7. 2001
    ..CONCLUSION: In patients with CF ages 6 months to 6 years, a single 300-mg dose of inhaled tobramycin appears to produce safe peak serum concentrations and drug concentrations in the bactericidal range in the lower respiratory tract...
  11. pmc Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis
    J W Krzewinski
    Division of Infectious Disease, Department of Pediatrics, Children's Hospital and Regional Medical Center and University of Washington, Seattle, Washington 98015, USA
    J Clin Microbiol 39:3597-602. 2001
    ....
  12. pmc Nucleotide sequence analysis of a gene from Burkholderia (Pseudomonas) cepacia encoding an outer membrane lipoprotein involved in multiple antibiotic resistance
    J L Burns
    Division of Infectious Disease, Children s Hospital and Medical Center, Seattle, Washington, USA
    Antimicrob Agents Chemother 40:307-13. 1996
    ..cepacia. The finding of multiple antibiotic resistance in B. cepacia as a result of an antibiotic efflux pump is surprising because it has long been believed that resistance in this organism is caused by impermeability to antibiotics...
  13. ncbi request reprint Transcytosis of gastrointestinal epithelial cells by Escherichia coli K1
    J L Burns
    Division of Infectious Disease, Children's Hospital and Regional Medical Center, 4800 Sand Point Way N.E, CH-32, Seattle, Washington 98105, USA
    Pediatr Res 49:30-7. 2001
    ..Caco-2 invasiveness correlated with length of time in tissue culture with maximum invasiveness demonstrated at 11 d in culture, when cells were polarized and differentiated...